Tranexamic Acid in Hip Fracture Patients: a Protocol for a Randomised, Placebo Controlled Trial on the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients

Overview

Journal BMJ Open

Specialty General Medicine

Date 2016 Jun 23

PMID 27329438

Citations 11

Authors

Elizabeth Bishop Gausden

Matthew R Garner

Stephen J Warner

Ashley Levack

Andrew M Nellestein

Tiffany Tedore

Eva Flores

Dean G Lorich

Affiliations

Soon will be listed here.

Abstract

Introduction: There is a high incidence of blood transfusion following hip fractures in elderly patients. Tranexamic acid (TXA) has proven efficacy in decreasing blood loss in general trauma patients as well as patients undergoing elective orthopaedic surgery. A randomised controlled trial will measure the effect of TXA in a population of patients undergoing hip fracture surgery.

Methods: This is a double-blinded, randomised placebo-controlled trial. Patients admitted through the emergency room that are diagnosed with an intertrochanteric or femoral neck fracture will be eligible for enrolment and randomised to either treatment with 1 g of intravenous TXA or intravenous saline at the time of skin incision. Patients undergoing percutaneous intervention for non-displaced or minimally displaced femoral neck fractures will not be eligible for enrolment. Postoperative transfusion rates will be recorded and blood loss will be calculated from serial haematocrits.

Ethics And Dissemination: This protocol was approved by the Institutional Review Board (IRB) and is registered with clinicaltrials.gov. The findings of the trial will be disseminated through peer-reviewed journals and conference presentations.

Trial Registration Number: NCT01940536.

Citing Articles

Global mapping of institutional and hospital-based (Level II-IV) arthroplasty registries: a scoping review.

Zgouridou A, Kenanidis E, Potoupnis M, Tsiridis E Eur J Orthop Surg Traumatol. 2023; 34(2):1219-1251.

PMID: 37768398 PMC: 10858160. DOI: 10.1007/s00590-023-03691-y.

Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures.

Gibbs V, Geneen L, Champaneria R, Raval P, Doree C, Brunskill S Cochrane Database Syst Rev. 2023; 6:CD013499.

PMID: 37272509 PMC: 10241722. DOI: 10.1002/14651858.CD013499.pub2.

Factors affecting the need of postoperative blood transfusion in elderly patients with intertrochanteric hip fracture.

Cho M, Cho Y, Song S Sci Prog. 2022; 105(4):368504221134429.

PMID: 36320187 PMC: 10450466. DOI: 10.1177/00368504221134429.

The effect of tranexamic acid on the reduction of intraoperative and postoperative blood loss and thromboembolic risk in patients with hip fracture.

Stojadinovic I, Ristic B, Knezevic D, Milenkovic Z, Prodanovic N, Zornic N Open Med (Wars). 2022; 17(1):857-862.

PMID: 35582194 PMC: 9055253. DOI: 10.1515/med-2022-0482.

Tranexamic acid use in pelvic and/or acetabular fracture surgery: A systematic review and meta-analysis.

Shu H, Mikula J, Yu A, Shafiq B J Orthop. 2021; 28:112-116.

PMID: 34924726 PMC: 8648565. DOI: 10.1016/j.jor.2021.11.018.

References

Foss N, Kehlet H . Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006; 88(8):1053-9. DOI: 10.1302/0301-620X.88B8.17534. View

Gillette B, DeSimone L, Trousdale R, Pagnano M, Sierra R . Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res. 2012; 471(1):150-4. PMC: 3528901. DOI: 10.1007/s11999-012-2488-z. View

Simmons J, Sikorski R, Pittet J . Tranexamic acid: from trauma to routine perioperative use. Curr Opin Anaesthesiol. 2015; 28(2):191-200. PMC: 4408016. DOI: 10.1097/ACO.0000000000000165. View

Cid J, Lozano M . Tranexamic acid reduces allogeneic red cell transfusions in patients undergoing total knee arthroplasty: results of a meta-analysis of randomized controlled trials. Transfusion. 2005; 45(8):1302-7. DOI: 10.1111/j.1537-2995.2005.00204.x. View

Duncan C, Gillette B, Jacob A, Sierra R, Sanchez-Sotelo J, Smith H . Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty. 2014; 30(2):272-6. DOI: 10.1016/j.arth.2014.08.022. View

Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M . Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014; 349:g4829. PMC: 4130961. DOI: 10.1136/bmj.g4829. View

George D, Sarraf K, Nwaboku H . Single perioperative dose of tranexamic acid in primary hip and knee arthroplasty. Eur J Orthop Surg Traumatol. 2014; 25(1):129-33. DOI: 10.1007/s00590-014-1457-5. View

Heyes G, Tucker A, Marley D, Foster A . Predictors for 1-year mortality following hip fracture: a retrospective review of 465 consecutive patients. Eur J Trauma Emerg Surg. 2015; 43(1):113-119. DOI: 10.1007/s00068-015-0556-2. View

Basques B, Toy J, Bohl D, Golinvaux N, Grauer J . General compared with spinal anesthesia for total hip arthroplasty. J Bone Joint Surg Am. 2015; 97(6):455-61. PMC: 4357526. DOI: 10.2106/JBJS.N.00662. View

10.

Hill G, Frawley W, Griffith K, Forestner J, Minei J . Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003; 54(5):908-14. DOI: 10.1097/01.TA.0000022460.21283.53. View

11.

Raksakietisak M, Sathitkarnmanee B, Srisaen P, Duangrat T, Chinachoti T, Rushatamukayanunt P . Two Doses of Tranexamic Acid Reduce Blood Transfusion in Complex Spine Surgery: A Prospective Randomized Study. Spine (Phila Pa 1976). 2015; 40(24):E1257-63. DOI: 10.1097/BRS.0000000000001063. View

12.

Emara W, Moez K, Elkhouly A . Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res. 2015; 8(1):48-53. PMC: 4173581. DOI: 10.4103/0259-1162.128908. View

13.

Shah M, Aharonoff G, Wolinsky P, Zuckerman J, Koval K . Outcome after hip fracture in individuals ninety years of age and older. J Orthop Trauma. 2001; 15(1):34-9. DOI: 10.1097/00005131-200101000-00007. View

14.

Eubanks J . Antifibrinolytics in major orthopaedic surgery. J Am Acad Orthop Surg. 2010; 18(3):132-8. View

15.

Kagoma Y, Crowther M, Douketis J, Bhandari M, Eikelboom J, Lim W . Use of antifibrinolytic therapy to reduce transfusion in patients undergoing orthopedic surgery: a systematic review of randomized trials. Thromb Res. 2008; 123(5):687-96. DOI: 10.1016/j.thromres.2008.09.015. View

16.

Foss N, Kristensen M, Kehlet H . Anaemia impedes functional mobility after hip fracture surgery. Age Ageing. 2008; 37(2):173-8. DOI: 10.1093/ageing/afm161. View

17.

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y . The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771):1096-101, 1101.e1-2. DOI: 10.1016/S0140-6736(11)60278-X. View

18.

Zufferey P, Miquet M, Quenet S, MARTIN P, Adam P, Albaladejo P . Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2009; 104(1):23-30. DOI: 10.1093/bja/aep314. View

19.

Nishihara S, Hamada M . Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?. Bone Joint J. 2015; 97-B(4):458-62. DOI: 10.1302/0301-620X.97B4.34656. View

20.

Yuan C, Zhang H, He S . Efficacy and safety of using antifibrinolytic agents in spine surgery: a meta-analysis. PLoS One. 2013; 8(11):e82063. PMC: 3838357. DOI: 10.1371/journal.pone.0082063. View